Low-dose erythromycin in the treatment of gastro-oesophageal reflux disease in infants. Apilot, randomised, double-blind, placebo-controlled trial

Abstract number: P1944

Banaszkiewicz A., Gawroñska A., Albrecht P., Radzikowski A.

Objectives: Gastro-oesophageal reflux disease (GERD) is defined as symptoms or complications of reflux of gastric content into the oesophageus. Commonly used medications for the treatment of GERD include acid-suppressant and prokinetic drugs. Based on systematic review, the literature supports the use of erythromycin as a prokinetic agent, however most reviewed trials were conducted in preterm infants.

The aim of this study was to assess the effectiveness of low-dose erythromycin in the treatment of gastro-oesophageal reflux (GERD) in full-term infants.

Methods: This was a double-blind, randomised, placebo-controlled clinical trial. Subjects aged 1–11 months with symptoms of GERD confirmed both by 24-hours pH-monitoring and the Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) were randomly assigned to receive either erythromycin at dose 1–3 mg/kg/dose or a comparable placebo. Both the active treatment and placebo were taken orally three times daily (20 minutes before meals) for 2 weeks. Parents were asked to fill out the I-GERQ-R at the study entry and at 2 and 4 weeks after enrollment.

Results: 24 infants were enrolled in the study, 12 in erythromycin group and 12 in placebo group; no significant difference was found between two groups. Difference in the I-GERQ-R score in erythromycin group compared with placebo group was statistically significant reduced (p = 0.000003) between beginning therapy and 4 weeks but was not between beginning therapy and 2 weeks (p = 0.07).

Conclusions: Erythromycin at dose 1–3 mg/kg/dose given three times daily was effective in treating GERD in full-term infants. Its effect seemed to be time-dependent.

Session Details

Date: 16/05/2009
Time: 00:00-00:00
Session name: 19th European Congress of Clinical Microbiology and Infectious Diseases
Location: Helsinki, Finland, 16 - 19 May 2009
Presentation type:
Back to top